Size-Dependent Uptake of Tc(I)-Labeled RGD Analogs

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$299,810.00
Award Year:
2005
Program:
STTR
Phase:
Phase I
Contract:
1R41CA112797-01
Award Id:
75471
Agency Tracking Number:
CA112797
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Molecular Insight Pharmaceuticals, Inc., 160 Second St, Cambridge, MA, 02142
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
DAVID VERA
(619) 543-5330
DVERA@UCSD.EDU
Business Contact:
(617) 492-5554
Research Institution:
UNIVERSITY OF CALIFORNIA SAN DIEGO

UNIVERSITY OF CALIFORNIA SAN DIEGO
9500 GILMAN DR, Dept. 0934
LA JOLLA, CA, 92093

Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): Anti-angiogenic therapy is currently one of the most active fields in cancer research. There are four basic approaches to limiting angiogenesis: blocking growth factors, inhibiting matrix proteases, directly targeting endothelial cells, and upregulating endogenous inhibitors. Although there is no simple answer to date for blocking angiogenesis, one approach now in clinical results is targeting integrin receptors (Vitaxin, EMD121974, & SB-265123 which target the alpha v, beta 3 integrin). Since the key biochemical parameter in angiogenesis has not been defined and is likely to be a different biochemical target in different tumor types, a molecular probe for the integrin receptor will be important in guiding the choice of patients for integrin receptor antagonist therapy. Five different molecular weight dextrans will be used to span the spectra of possible permeabilities. One set of dextrans will be labeled with both the RGD peptide and Tc-99m. The other set of dextrans will be labeled with RGE and Tc-99m and will serve as a control because changing the molecular weight of the dextran can result in "localization" that is heavily dependent on the permeability of the molecule rather than the specific binding of the RGD peptide to the integrin receptor. This control molecule will therefore serve as a reference for non-integrin receptor processes much like the "reference tissue" model is used in positron emission tomography (PET) neurochemistry imaging. In that case, a tissue that does not contain the target receptor is used as a reference whereas in this study, the dextran control without the RGD peptide will serve as the reference.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government